$ARM

Wall Street Analysts Are Bullish on Top Technology Picks

Analysts maintained Buy ratings on ARM (ARM) and Dynatrace (DT). ARM's price target set at $480 by Bernstein, consensus at $299.47. Dynatrace's target at $62 by BMO, consensus at $60.46. Both stocks have Strong Buy consensus.

Original reporting
Published Sep 16, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 11:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street Analysts Are Bullish on Top Technology Picks — source image
Decision brief

The 30-second read

$ARMBullishMed
01

Why it matters

Analyst upgrades can act as catalysts, especially when accompanied by high price targets, potentially driving short‑term buying pressure.

02

Market read

Fresh analyst coverage adds new price targets, offering actionable insight for traders focusing on tech stocks.

03

What to watch

No new fundamental data; rating relies on forward expectations.

Relevance 7/10Novelty 6/10Timing: today

Background

The article aggregates recent bullish analyst ratings for two technology companies, ARM and Dynatrace, providing price targets and rating consensus.

Company-level read

Ticker impact

$ARMBullishMedium confidence
Context

Bernstein analyst David Dai maintained a Buy rating on ARM and set a $480 price target, new analyst coverage disclosed today.

Expected impact

Target price suggests a bullish move; price could rise toward $480 if market follows the rating.

Evidence & confidence

Analyst rating and high price target provide fresh catalyst for investors.

$DTBullishMedium confidence
Context

BMO Capital analyst Keith Bachman maintained a Buy rating on Dynatrace with a $62 price target, new rating disclosed today.

Expected impact

Price may move toward $62 as investors digest the rating.

Evidence & confidence

Fresh analyst endorsement and target price create a short‑term bullish signal.

Market effects

Positive analyst sentiment may lift broader technology sector sentiment.

U.S. market focus; limited regional effect.

May influence global tech investors tracking U.S. ADRs.

Counterpoint

Price targets may be overly optimistic given recent market volatility.

Key entities

  • Bernstein

    Provided Buy rating and $480 target for ARM.

  • BMO Capital

    Provided Buy rating and $62 target for Dynatrace.

Related articles

$ARMMed

Arm CEO says he's more confident its new AI chip can meet a loftier $2B revenue goal

Arm CEO Rene Haas expressed growing confidence in meeting a $2B revenue target for its new AGI CPU, citing improved supply chain visibility. The company had previously doubled its revenue outlook to $2B, with demand not being the primary concern but rather securing manufacturing capacity. Arm's stock has fluctuated based on these updates, with a 10% drop in May and a 7% rise in July.

$DTMed

Why Dynatrace (DT) Stock Is Trading Up Today

Dynatrace (DT) stock rose 3.4% after announcing a partnership with Sopra Steria for European IT management and compliance. UBS reiterated a Buy rating with a $65 target. DT shares are up 28.6% YTD, near a 52-week high. The company's stock has shown volatility, with 15 moves over 5% in the past year.

$ARMLowAI 8/10

Arm Stock Is Down More Than 40%. Here's Why I'm Staying on the Sidelines.

Arm Holdings' stock fell 10% on Monday, now 40% below its 52-week high, amid a broader AI sector sell-off. The company reported record Q1 2027 revenue of $1.29B, up 22% YoY, with royalties and licensing revenue growing 22% and 23% respectively. However, smartphone sales slowdowns are pressuring royalty growth. The stock trades at 79x next fiscal year's expected earnings, raising valuation concerns.

$ARMMed

Prediction: Arm Could Be the Picks

Arm (ARM) trades at $265 with a $280 price target, up 142% YTD. Q1 FY2027 revenue grew 22% YoY to $1.29B, with data center royalties doubling. Bull case targets $420, but risks include high valuation (forward P/E 120) and litigation with Qualcomm. Analysts rate it a buy with 5.81% upside.